Background: Several studies reported serological cross-reaction between DENV and SARS-CoV-2 IgG antibodies using rapid point of care (POC) assays . Limited data are available about cross-reactivity when testing is done using advanced chemiluminescence immunoassay (CLIA) and ELISA assays .
Objective: This study aims to investigate potential serological cross-reactivity between SARS-CoV-2-IgG and DENV-IgG using CLIA and ELISA assays . Study-design: A total of 90 DENV-IgG-ELISA positive and 90 negative pre-pandemic sera were tested for anti-SARS-CoV-2-IgG using the automated CL-900i CLIA assay . Furthermore, a total of 91 SARS-CoV-2-IgG-CLIA positive and 91 negative post-pandemic sera were tested for anti-DENV-IgG using the Novalis ELISA assay .
Results: The DENV-IgG positive sera had 5 positives and 85 negatives for SARS-CoV-2-IgG . The DENV-IgG negative sera also had 5 positives and 85 negatives for SARS-CoV-2-IgG . No statistically significant difference in specificity between the DENV-IgG positive and DENV-IgG negative sera was found (p-value=1.00). The SARS-CoV-2-IgG positive sera had 43 positives , 47 negatives, and 1 equivocal for DENV-IgG . The SARS-CoV-2-IgG negative sera had 50 positives , 40 negatives, and 1 equivocal for DENV-IgG . No statistically significant difference in the proportion that is DENV-IgG positive between the SARS-CoV-2-IgG positive and SARS-CoV-2-IgG negative sera (p-value=0.58).
Conclusions: No evidence for cross-reactivity between the DENV and SARS-CoV-2 IgG antibodies was found.